ESSA Pharmaceuticals, Inc.

84 articles with ESSA Pharmaceuticals, Inc.

• ESSA Pharma Grants Stock Options - Oct. 30, 2019

  10/30/2019

  ESSA Pharma Inc. announced that, pursuant to its stock option plan, it has granted incentive stock options to non – executive members of the Corporation's board of directors to purchase up to an aggregate of 225,000 common shares in the capital of the Corporation.

• ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  10/28/2019

  ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today in Boston will present new preclinical data on ESSA's lead Investigational New Drug ("IND") candidate at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

• ESSA Announces Changes to its Board of Directors

  10/18/2019

  ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announces that Ari Brettman has been appointed to the board of the directors of the Company (the "Board") pursuant to a nomination right granted to Clarus Lifesciences III, L.P., now managed by Blackstone Life Sciences.

• ESSA Pharma Board of Directors Approves Stock Option Plan, RSU Plan and Option Grants

  10/7/2019

  The Options are exercisable on or before October 4, 2029 at the price of US$3.23 per Common share and are granted in accordance with the polices of the TSX Venture Exchange and the terms and conditions of the Existing Option Plan.

• ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress

  9/28/2019

  ESSA Pharma Inc. presented new preclinical data on ESSA's lead Investigational New Drug candidate at the 2019 American Urological Association Annual Meeting.

• ESSA to Present at Ladenburg Thalmann Healthcare Conference

  9/19/2019

  Dr. David. R. Parkinson, Chief Executive Officer, will provide a corporate overview of the Company's business and will be available for one-on-one meetings from on September 24, 2019. 

• ESSA Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference

  9/5/2019

  ESSA Pharma Inc. announced the Company will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference on Monday September 9, 2019 at 5:05pm EDT at the Lotte New York Palace Hotel in New York.

• ESSA Pharma Completes Public Offering and Concurrent Private Placement for Aggregate Gross Proceeds of US$36 Million

  8/27/2019

  ESSA Pharma Inc. (NASDAQ: EPIX; TSXV: EPI) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to its previously announced equity offering, it has closed a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States for aggregate gross proceeds of US$36 million (the "Offering").

• ESSA Pharma Announces $36 Million Public Offering of Common Stock and Concurrent Private Placement

  8/23/2019

  ESSA Pharma Inc. (NASDAQ: EPIX; TSXV: EPI) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States (the "Offering").

• ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2019

  8/14/2019

  ESSA Pharma Inc. ("ESSA", or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2019

• ESSA Announces that the Scheme of Arrangement with Realm Therapeutics has become Effective

  7/31/2019

  ESSA Pharma Inc., a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to the announcement made on July 30, 2019, the scheme of arrangement under Part 26 of the U.K. Companies Act 2006 has become effective and ESSA has acquired all of the issued and outstanding shares of Realm Therapeutics plc.

• ESSA Announces Court Sanction of the Scheme of Arrangement with Realm Therapeutics

  7/30/2019

  ESSA Pharma Inc. is pleased to announce that, further to the announcement made on July 8, 2019, the High Court of Justice in England and Wales has today sanctioned the scheme of arrangement under Part 26 of the U.K. Companies Act 2006, pursuant to which ESSA will acquire all of the issued and outstanding shares of Realm Therapeutics plc.

• ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer

  7/15/2019

  ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on the developing novel therapies for the treatment of prostate cancer, announced today the appointment of Dr. Alessandra Cesano, M.D., PhD as Chief Medical Officer ("CMO"). 

• ESSA Pharma Inc. Reports Results of Annual General Meeting of Shareholders

  6/26/2019

  ESSA Pharma Inc., a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its annual general meeting of shareholders of the Company held on June 25, 2019 in Vancouver, British Columbia, Canada.

• ESSA Provides an Update to the Acquisition of Realm Therapeutics

  6/26/2019

  ESSA Pharma Inc., a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer provides an update, further to the announcement made on May 16, 2019 announcing the acquisition of Realm Therapeutics plc by ESSA pursuant to a scheme of arrangement under Part 26 of the U.K. Companies Act 2006.

• Agreement Reached for ESSA Pharma to Acquire Realm Therapeutics

  5/16/2019

  ESSA Pharma Inc. announced that it has entered into a definitive agreement with Realm Therapeutics plc setting forth the terms of an acquisition whereby ESSA will acquire all of the issued and outstanding shares of Realm in an all-stock transaction.

• Preclinical Data Highlighting Therapeutic Potential of EPI-7386 Presented at 2019 American Urological Association Annual Meeting

  5/4/2019

  ESSA Pharma Inc. presented new preclinical data on ESSA's lead Investigational New Drug candidate at the 2019 American Urological Association Annual Meeting.

• ESSA Pharma to Attend Bloom Burton & Co. Healthcare Investor Conference 2019

  4/25/2019

  ESSA Pharma Inc., a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting Bloom Burton & Co. Healthcare Investor Conference on Wednesday May 1 at 10:30am Eastern Standard Time at the Metro Toronto Convention Centre in Toronto, Ontario, Canada.

• ESSA Pharma Announces Abstract Presentation at the 2019 American Urological Association Annual Meeting

  4/17/2019

  ESSA Pharma Inc. announced an abstract on ESSA's aniten compounds for metastatic castration-resistant prostate cancer has been selected for a moderated poster presentation at the upcoming 2019 American Urological Association Annual Meeting from May 3-6 in Chicago, Illinois.

• ESSA Pharma Grants Stock Options

  4/12/2019

  ESSA Pharma Inc. announced that, pursuant to its stock option plan, it has granted incentive stock options to directors and officers, employees and consults of the Corporation to purchase up to an aggregate of 238,000 common shares in the capital of the Corporation.